Which potent side effect is associated with the use of atypical antipsychotics compared to typical antipsychotics in pregnancy?

The use of atypical antipsychotics during pregnancy is associated with an increased risk of gestational metabolic complications, making this the correct choice. Atypical antipsychotics, such as olanzapine and quetiapine, are known to contribute to weight gain and changes in metabolic parameters, which can lead to complications such as gestational diabetes and hypertension in pregnant individuals.

The mechanisms behind these complications may relate to the effects these medications have on neurotransmitter systems that can affect appetite, metabolism, and insulin sensitivity. Managing weight and metabolic health is crucial during pregnancy for both maternal and fetal well-being, which is why the increased risk of these complications is a significant concern.

Faster resolution of psychosis, lower birth weight, and improved maternal mental health are not direct side effects associated with the use of atypical antipsychotics in this population. The resolution of psychosis can vary and is not specifically linked to the drug's classification as atypical or typical. Both typical and atypical antipsychotics can potentially impact birth weight, but it is the metabolic complications associated with atypical antipsychotics that raise more immediate concerns in managing pregnant patients. Improved maternal mental health is the goal of treatment but does not highlight a